Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study

The 21-gene Recurrence Score assay is validated to predict recurrence risk and chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To determine prospective breast-cancer-specific mortality (BCSM) outcomes by baseline Recurrence Score results and clinical covariates, the N...

Descripción completa

Detalles Bibliográficos
Autores principales: Petkov, Valentina I, Miller, Dave P, Howlader, Nadia, Gliner, Nathan, Howe, Will, Schussler, Nicola, Cronin, Kathleen, Baehner, Frederick L, Cress, Rosemary, Deapen, Dennis, Glaser, Sally L, Hernandez, Brenda Y, Lynch, Charles F, Mueller, Lloyd, Schwartz, Ann G, Schwartz, Stephen M, Stroup, Antoinette, Sweeney, Carol, Tucker, Thomas C, Ward, Kevin C, Wiggins, Charles, Wu, Xiao-Cheng, Penberthy, Lynne, Shak, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515329/
https://www.ncbi.nlm.nih.gov/pubmed/28721379
http://dx.doi.org/10.1038/npjbcancer.2016.17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515329/
https://www.ncbi.nlm.nih.gov/pubmed/28721379
http://dx.doi.org/10.1038/npjbcancer.2016.17

Ejemplares similares